Compare INKT & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INKT | GROW |
|---|---|---|
| Founded | 2017 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.6M | 32.7M |
| IPO Year | 2021 | 1995 |
| Metric | INKT | GROW |
|---|---|---|
| Price | $12.27 | $3.07 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 39.1K | 38.7K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $23,850,609.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.81 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.80 | $2.23 |
| 52 Week High | $76.00 | $3.65 |
| Indicator | INKT | GROW |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 66.41 |
| Support Level | $10.82 | $2.37 |
| Resistance Level | $12.68 | $3.43 |
| Average True Range (ATR) | 0.88 | 0.12 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 56.37 | 70.14 |
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.